Cargando…

Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience

Immune checkpoint inhibitors (ICIs), pembrolizumab in particular, have been shown to be vastly more efficacious than traditional cytotoxic or platinum-based chemotherapies in the treatment of non-small cell lung cancer (NSCLC). While there are plenty of data showing their efficacy and safety profile...

Descripción completa

Detalles Bibliográficos
Autores principales: Shalata, Walid, Zolnoorian, Jeremy, Migliozzi, Gabrielle, Jama, Ashraf Abu, Dudnik, Yulia, Cohen, Ahron Yehonatan, Meirovitz, Amichay, Yakobson, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056863/
https://www.ncbi.nlm.nih.gov/pubmed/36983011
http://dx.doi.org/10.3390/ijms24065938
_version_ 1785016227062611968
author Shalata, Walid
Zolnoorian, Jeremy
Migliozzi, Gabrielle
Jama, Ashraf Abu
Dudnik, Yulia
Cohen, Ahron Yehonatan
Meirovitz, Amichay
Yakobson, Alexander
author_facet Shalata, Walid
Zolnoorian, Jeremy
Migliozzi, Gabrielle
Jama, Ashraf Abu
Dudnik, Yulia
Cohen, Ahron Yehonatan
Meirovitz, Amichay
Yakobson, Alexander
author_sort Shalata, Walid
collection PubMed
description Immune checkpoint inhibitors (ICIs), pembrolizumab in particular, have been shown to be vastly more efficacious than traditional cytotoxic or platinum-based chemotherapies in the treatment of non-small cell lung cancer (NSCLC). While there are plenty of data showing their efficacy and safety profiles, very little exists about the long-term effects of pembrolizumab. We compiled all patients with NSCLC who were treated with pembrolizumab at our institution and had progression-free survival (PFS) of at least 2 years during or after the treatment period. Within this group, we examined the long-term rates of PFS and overall survival (OS), side effect profiles, treatment, and overall disease course up to 60 months after starting treatment. This study included 36 patients with median (range) follow up times from treatment initiation in months as follows: 36 (28–65) overall; 39.5 (28–65) for adenocarcinoma; and 36 (30–58) for squamous cell carcinoma. The median (range) of OS and PFS (months) was comparable for adenocarcinoma, 36 (23–55); and squamous cell carcinoma, 35.5 (28–65). Overall, pembrolizumab shows remarkable long-term safety and efficacy in NSCLC patients. In patients who show an initially strong response and can make it to 24 months of PFS, disease progression after this period seems increasingly unlikely.
format Online
Article
Text
id pubmed-10056863
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100568632023-03-30 Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience Shalata, Walid Zolnoorian, Jeremy Migliozzi, Gabrielle Jama, Ashraf Abu Dudnik, Yulia Cohen, Ahron Yehonatan Meirovitz, Amichay Yakobson, Alexander Int J Mol Sci Article Immune checkpoint inhibitors (ICIs), pembrolizumab in particular, have been shown to be vastly more efficacious than traditional cytotoxic or platinum-based chemotherapies in the treatment of non-small cell lung cancer (NSCLC). While there are plenty of data showing their efficacy and safety profiles, very little exists about the long-term effects of pembrolizumab. We compiled all patients with NSCLC who were treated with pembrolizumab at our institution and had progression-free survival (PFS) of at least 2 years during or after the treatment period. Within this group, we examined the long-term rates of PFS and overall survival (OS), side effect profiles, treatment, and overall disease course up to 60 months after starting treatment. This study included 36 patients with median (range) follow up times from treatment initiation in months as follows: 36 (28–65) overall; 39.5 (28–65) for adenocarcinoma; and 36 (30–58) for squamous cell carcinoma. The median (range) of OS and PFS (months) was comparable for adenocarcinoma, 36 (23–55); and squamous cell carcinoma, 35.5 (28–65). Overall, pembrolizumab shows remarkable long-term safety and efficacy in NSCLC patients. In patients who show an initially strong response and can make it to 24 months of PFS, disease progression after this period seems increasingly unlikely. MDPI 2023-03-21 /pmc/articles/PMC10056863/ /pubmed/36983011 http://dx.doi.org/10.3390/ijms24065938 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shalata, Walid
Zolnoorian, Jeremy
Migliozzi, Gabrielle
Jama, Ashraf Abu
Dudnik, Yulia
Cohen, Ahron Yehonatan
Meirovitz, Amichay
Yakobson, Alexander
Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience
title Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience
title_full Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience
title_fullStr Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience
title_full_unstemmed Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience
title_short Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience
title_sort long-lasting therapeutic response following treatment with pembrolizumab in patients with non-small cell lung cancer: a real-world experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056863/
https://www.ncbi.nlm.nih.gov/pubmed/36983011
http://dx.doi.org/10.3390/ijms24065938
work_keys_str_mv AT shalatawalid longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience
AT zolnoorianjeremy longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience
AT migliozzigabrielle longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience
AT jamaashrafabu longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience
AT dudnikyulia longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience
AT cohenahronyehonatan longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience
AT meirovitzamichay longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience
AT yakobsonalexander longlastingtherapeuticresponsefollowingtreatmentwithpembrolizumabinpatientswithnonsmallcelllungcancerarealworldexperience